115 related articles for article (PubMed ID: 36468173)
1. Trends and future projections of cervical cancer-related outcomes in Japan: What happens if the HPV vaccine program is not implemented?
Sakakibara A; Nakayama T; Uchida H; Odagiri Y; Ito Y; Katayama T; Ueda Y; Higuchi T; Terakawa K; Matsui K; Miyazaki K; Konishi I
Int J Cancer; 2023 May; 152(9):1863-1874. PubMed ID: 36468173
[TBL] [Abstract][Full Text] [Related]
2. A nationwide birth year-by-year analysis of effectiveness of HPV vaccine in Japan.
Yagi A; Ueda Y; Nakagawa S; Masuda T; Miyatake T; Ikeda S; Abe H; Hirai K; Sekine M; Miyagi E; Enomoto T; Nakayama T; Kimura T
Cancer Sci; 2021 Sep; 112(9):3691-3698. PubMed ID: 34252250
[TBL] [Abstract][Full Text] [Related]
3. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
4. Declining rates of cervical intraepithelial neoplasia in British Columbia, Canada: An ecological analysis on the effects of the school-based human papillomavirus vaccination program.
Donken R; van Niekerk D; Hamm J; Spinelli JJ; Smith L; Sadarangani M; Albert A; Money D; Dobson S; Miller D; Lee M; Mitchell-Foster S; Krajden M; Naus M; Ogilvie G
Int J Cancer; 2021 Jul; 149(1):191-199. PubMed ID: 33586169
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
6. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
7. Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland.
Kind AB; Pavelyev A; Kothari S; El Mouaddin N; Schmidt A; Morais E; Guggisberg P; Lienert F
BMC Public Health; 2020 May; 20(1):671. PubMed ID: 32398057
[TBL] [Abstract][Full Text] [Related]
8. Impact of human papillomavirus vaccine on cervical cancer epidemic: Evidence from the surveillance, epidemiology, and end results program.
Pei J; Shu T; Wu C; Li M; Xu M; Jiang M; Zhu C
Front Public Health; 2022; 10():998174. PubMed ID: 36684904
[TBL] [Abstract][Full Text] [Related]
9. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.
Hildesheim A; Gonzalez P; Kreimer AR; Wacholder S; Schussler J; Rodriguez AC; Porras C; Schiffman M; Sidawy M; Schiller JT; Lowy DR; Herrero R;
Am J Obstet Gynecol; 2016 Aug; 215(2):212.e1-212.e15. PubMed ID: 26892991
[TBL] [Abstract][Full Text] [Related]
10. Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015.
Cleveland AA; Gargano JW; Park IU; Griffin MR; Niccolai LM; Powell M; Bennett NM; Saadeh K; Pemmaraju M; Higgins K; Ehlers S; Scahill M; Johnson Jones ML; Querec T; Markowitz LE; Unger ER;
Int J Cancer; 2020 Feb; 146(3):810-818. PubMed ID: 30980692
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus vaccine to prevent cervical intraepithelial neoplasia in Japan: A nationwide case-control study.
Ikeda S; Ueda Y; Hara M; Yagi A; Kitamura T; Kitamura Y; Konishi H; Kakizoe T; Sekine M; Enomoto T; Sobue T
Cancer Sci; 2021 Feb; 112(2):839-846. PubMed ID: 33040433
[TBL] [Abstract][Full Text] [Related]
12. Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis.
Ogilvie GS; Naus M; Money DM; Dobson SR; Miller D; Krajden M; van Niekerk DJ; Coldman AJ
Int J Cancer; 2015 Oct; 137(8):1931-7. PubMed ID: 25754686
[TBL] [Abstract][Full Text] [Related]
13. The impact of bivalent HPV vaccine on cervical intraepithelial neoplasia by deprivation in Scotland: reducing the gap.
Cameron RL; Kavanagh K; Cameron Watt D; Robertson C; Cuschieri K; Ahmed S; Pollock KG
J Epidemiol Community Health; 2017 Oct; 71(10):954-960. PubMed ID: 28756395
[TBL] [Abstract][Full Text] [Related]
14. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Lehtinen M; Paavonen J; Wheeler CM; Jaisamrarn U; Garland SM; Castellsagué X; Skinner SR; Apter D; Naud P; Salmerón J; Chow SN; Kitchener H; Teixeira JC; Hedrick J; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; De Carvalho NS; Germar MJ; Peters K; Mindel A; De Sutter P; Bosch FX; David MP; Descamps D; Struyf F; Dubin G;
Lancet Oncol; 2012 Jan; 13(1):89-99. PubMed ID: 22075171
[TBL] [Abstract][Full Text] [Related]
15. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths.
Van Kriekinge G; Castellsagué X; Cibula D; Demarteau N
Vaccine; 2014 Feb; 32(6):733-9. PubMed ID: 24291200
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of future cervical cancer risk in Japan, based on birth year.
Yagi A; Ueda Y; Ikeda S; Sekine M; Nakayama T; Miyagi E; Enomoto T
Vaccine; 2019 May; 37(22):2889-2891. PubMed ID: 31027925
[TBL] [Abstract][Full Text] [Related]
17. Incidence of cervical precancerous lesions and cervical cancer in Denmark from 2000 to 2019: Population impact of multi-cohort vaccination against human papillomavirus infection.
Ring LL; Munk C; Galanakis M; Tota JE; Thomsen LT; Kjaer SK
Int J Cancer; 2023 Apr; 152(7):1320-1327. PubMed ID: 36250312
[TBL] [Abstract][Full Text] [Related]
18. What's next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination.
Lynge E; Antilla A; Arbyn M; Segnan N; Ronco G
Eur J Cancer; 2009 Oct; 45(15):2714-21. PubMed ID: 19695870
[TBL] [Abstract][Full Text] [Related]
19. Cervical Intraepithelial Neoplasia Rates in British Columbia Women: A Population-Level Data Linkage Evaluation of the School-Based HPV Immunization Program.
Racey CS; Albert A; Donken R; Smith L; Spinelli JJ; Pedersen H; de Bruin P; Masaro C; Mitchell-Foster S; Sadarangani M; Dawar M; Krajden M; Naus M; van Niekerk D; Ogilvie G
J Infect Dis; 2020 Jan; 221(1):81-90. PubMed ID: 31504649
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus vaccine impact on invasive cervical cancer in Japan: Preliminary results from cancer statistics and the MINT study.
Onuki M; Takahashi F; Iwata T; Nakazawa H; Yahata H; Kanao H; Horie K; Konnai K; Nio A; Takehara K; Kamiura S; Tsuda N; Takei Y; Shigeta S; Matsumura N; Yoshida H; Motohara T; Yamazaki H; Nakamura K; Hamanishi J; Tasaka N; Ishikawa M; Hirashima Y; Kudaka W; Mori-Uchino M; Kukimoto I; Fujii T; Watanabe Y; Noda K; Yoshikawa H; Yaegashi N; Matsumoto K;
Cancer Sci; 2023 Nov; 114(11):4426-4432. PubMed ID: 37688310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
